Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies)
详细信息 查看全文
- 作者：Tamio Teramoto ; MD ; PhDa ; ttera@med.teikyo-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Masahiko Kobayashi ; RPh ; MSb ; Kiyoko Uno ; MD ; PhDc ; Yoshiharu Takagi ; MSd ; Osamu Matsuoka ; MDe ; Masayuki Sugimoto ; MDf ; Satoshi Inoue ; MDg ; Fumiko Minami ; MDh ; Marie Thé ; rè ; se Baccara-Dinet ; MD ; MSci
- 刊名：The American Journal of Cardiology
- 出版年：2016
- 出版时间：1 July 2016
- 年：2016
- 卷：118
- 期：1
- 页码：56-63
- 全文大小：302 K
文摘
- •
Alirocumab reduced low-density lipoprotein cholesterol (LDL-C) in Japanese healthy male subjects.
- •
Alirocumab reduced LDL-C by 54.8% to 71.7% in patients with hypercholesterolemia.
- •
No safety or tolerability concerns were apparent with alirocumab.